Cargando…

Systolic Blood Pressure and Effects of Screening for Atrial Fibrillation With Long-Term Continuous Monitoring (a LOOP Substudy)

BACKGROUND: Hypertension is a well-known risk factor for atrial fibrillation (AF) and stoke, but data on the interaction between systolic blood pressure (SBP) and effects of AF screening are lacking. METHODS: The LOOP Study randomized AF-naïve individuals aged 70 to 90 years with additional stroke r...

Descripción completa

Detalles Bibliográficos
Autores principales: Xing, Lucas Yixi, Diederichsen, Søren Zöga, Højberg, Søren, Krieger, Derk W., Graff, Claus, Olesen, Morten Salling, Brandes, Axel, Køber, Lars, Haugan, Ketil Jørgen, Svendsen, Jesper Hastrup
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9370254/
https://www.ncbi.nlm.nih.gov/pubmed/35862138
http://dx.doi.org/10.1161/HYPERTENSIONAHA.122.19333
_version_ 1784766736205086720
author Xing, Lucas Yixi
Diederichsen, Søren Zöga
Højberg, Søren
Krieger, Derk W.
Graff, Claus
Olesen, Morten Salling
Brandes, Axel
Køber, Lars
Haugan, Ketil Jørgen
Svendsen, Jesper Hastrup
author_facet Xing, Lucas Yixi
Diederichsen, Søren Zöga
Højberg, Søren
Krieger, Derk W.
Graff, Claus
Olesen, Morten Salling
Brandes, Axel
Køber, Lars
Haugan, Ketil Jørgen
Svendsen, Jesper Hastrup
author_sort Xing, Lucas Yixi
collection PubMed
description BACKGROUND: Hypertension is a well-known risk factor for atrial fibrillation (AF) and stoke, but data on the interaction between systolic blood pressure (SBP) and effects of AF screening are lacking. METHODS: The LOOP Study randomized AF-naïve individuals aged 70 to 90 years with additional stroke risk factors to either screening with implantable loop recorder (ILR) and anticoagulation initiation upon detection of AF episodes ≥6 minutes, or usual care. In total, 5997 participants with available baseline SBP measurements were included in this substudy. Outcomes were analyzed according to the time-to-first-event principle using cause-specific Cox models. RESULTS: The hazard ratio of stroke or systemic arterial embolism for ILR versus control decreased with increasing SBP. ILR screening yielded a 44% risk reduction of stroke or systemic arterial embolism among participants with SBP ≥150 mm Hg (adjusted hazard ratio, 0.56 [0.37–0.83]). Within the ILR group, SBP≥150 mm Hg was associated with a higher incidence of AF episodes ≥24 hours than lower SBP (adjusted hazard ratio, 1.70 [1.08–2.69]) but not with the overall occurrence of AF (adjusted P>0.05). CONCLUSIONS: The impact of AF screening on thromboembolic events increased with increasing blood pressure. SBP≥150 mm Hg was associated with a >1.5-fold increased risk of AF episodes ≥24 hours, along with an almost 50% risk reduction of stroke or systemic arterial embolism by ILR screening compared to lower blood pressure. These findings should be considered hypothesis-generating and warrant further study. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique Identifier: NCT02036450.
format Online
Article
Text
id pubmed-9370254
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-93702542022-08-12 Systolic Blood Pressure and Effects of Screening for Atrial Fibrillation With Long-Term Continuous Monitoring (a LOOP Substudy) Xing, Lucas Yixi Diederichsen, Søren Zöga Højberg, Søren Krieger, Derk W. Graff, Claus Olesen, Morten Salling Brandes, Axel Køber, Lars Haugan, Ketil Jørgen Svendsen, Jesper Hastrup Hypertension Original Articles BACKGROUND: Hypertension is a well-known risk factor for atrial fibrillation (AF) and stoke, but data on the interaction between systolic blood pressure (SBP) and effects of AF screening are lacking. METHODS: The LOOP Study randomized AF-naïve individuals aged 70 to 90 years with additional stroke risk factors to either screening with implantable loop recorder (ILR) and anticoagulation initiation upon detection of AF episodes ≥6 minutes, or usual care. In total, 5997 participants with available baseline SBP measurements were included in this substudy. Outcomes were analyzed according to the time-to-first-event principle using cause-specific Cox models. RESULTS: The hazard ratio of stroke or systemic arterial embolism for ILR versus control decreased with increasing SBP. ILR screening yielded a 44% risk reduction of stroke or systemic arterial embolism among participants with SBP ≥150 mm Hg (adjusted hazard ratio, 0.56 [0.37–0.83]). Within the ILR group, SBP≥150 mm Hg was associated with a higher incidence of AF episodes ≥24 hours than lower SBP (adjusted hazard ratio, 1.70 [1.08–2.69]) but not with the overall occurrence of AF (adjusted P>0.05). CONCLUSIONS: The impact of AF screening on thromboembolic events increased with increasing blood pressure. SBP≥150 mm Hg was associated with a >1.5-fold increased risk of AF episodes ≥24 hours, along with an almost 50% risk reduction of stroke or systemic arterial embolism by ILR screening compared to lower blood pressure. These findings should be considered hypothesis-generating and warrant further study. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique Identifier: NCT02036450. Lippincott Williams & Wilkins 2022-07-08 2022-09 /pmc/articles/PMC9370254/ /pubmed/35862138 http://dx.doi.org/10.1161/HYPERTENSIONAHA.122.19333 Text en © 2022 The Authors. https://creativecommons.org/licenses/by/4.0/Hypertension is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited. This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.
spellingShingle Original Articles
Xing, Lucas Yixi
Diederichsen, Søren Zöga
Højberg, Søren
Krieger, Derk W.
Graff, Claus
Olesen, Morten Salling
Brandes, Axel
Køber, Lars
Haugan, Ketil Jørgen
Svendsen, Jesper Hastrup
Systolic Blood Pressure and Effects of Screening for Atrial Fibrillation With Long-Term Continuous Monitoring (a LOOP Substudy)
title Systolic Blood Pressure and Effects of Screening for Atrial Fibrillation With Long-Term Continuous Monitoring (a LOOP Substudy)
title_full Systolic Blood Pressure and Effects of Screening for Atrial Fibrillation With Long-Term Continuous Monitoring (a LOOP Substudy)
title_fullStr Systolic Blood Pressure and Effects of Screening for Atrial Fibrillation With Long-Term Continuous Monitoring (a LOOP Substudy)
title_full_unstemmed Systolic Blood Pressure and Effects of Screening for Atrial Fibrillation With Long-Term Continuous Monitoring (a LOOP Substudy)
title_short Systolic Blood Pressure and Effects of Screening for Atrial Fibrillation With Long-Term Continuous Monitoring (a LOOP Substudy)
title_sort systolic blood pressure and effects of screening for atrial fibrillation with long-term continuous monitoring (a loop substudy)
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9370254/
https://www.ncbi.nlm.nih.gov/pubmed/35862138
http://dx.doi.org/10.1161/HYPERTENSIONAHA.122.19333
work_keys_str_mv AT xinglucasyixi systolicbloodpressureandeffectsofscreeningforatrialfibrillationwithlongtermcontinuousmonitoringaloopsubstudy
AT diederichsensørenzoga systolicbloodpressureandeffectsofscreeningforatrialfibrillationwithlongtermcontinuousmonitoringaloopsubstudy
AT højbergsøren systolicbloodpressureandeffectsofscreeningforatrialfibrillationwithlongtermcontinuousmonitoringaloopsubstudy
AT kriegerderkw systolicbloodpressureandeffectsofscreeningforatrialfibrillationwithlongtermcontinuousmonitoringaloopsubstudy
AT graffclaus systolicbloodpressureandeffectsofscreeningforatrialfibrillationwithlongtermcontinuousmonitoringaloopsubstudy
AT olesenmortensalling systolicbloodpressureandeffectsofscreeningforatrialfibrillationwithlongtermcontinuousmonitoringaloopsubstudy
AT brandesaxel systolicbloodpressureandeffectsofscreeningforatrialfibrillationwithlongtermcontinuousmonitoringaloopsubstudy
AT køberlars systolicbloodpressureandeffectsofscreeningforatrialfibrillationwithlongtermcontinuousmonitoringaloopsubstudy
AT hauganketiljørgen systolicbloodpressureandeffectsofscreeningforatrialfibrillationwithlongtermcontinuousmonitoringaloopsubstudy
AT svendsenjesperhastrup systolicbloodpressureandeffectsofscreeningforatrialfibrillationwithlongtermcontinuousmonitoringaloopsubstudy